How to use FDA’s safety-labeling changes database for peptide drugs

01

What the SrLC database contains

The database records updates to safety information for human prescription drugs under new drug applications and certain prescription biological products under biologics license applications. FDA says coverage begins in January 2016. Entries can include labeling and efficacy supplement approvals initiated by an applicant or FDA, along with safety labeling changes required under federal law.

Covered sections include Boxed Warning, Contraindications, Warnings and Precautions, Adverse Reactions, Drug Interactions, Use in Specific Populations, Patient Counseling Information, Patient Information, and Medication Guides. A record can therefore show exactly what language was added, revised, or removed and when FDA approved that change.

That precision is useful for researching approved peptide and peptide-related drugs. It allows an editor to replace a vague statement such as “FDA changed the warning” with the exact product, section, action date, old language, new language, and source.

02

What the database leaves out

FDA lists important exclusions. The database does not cover updates to nonsafety sections such as Indications and Usage or Dosage and Administration. It does not include generic products regulated under abbreviated new drug applications, nonprescription drugs, original NDA or BLA safety labeling, or certain products regulated by FDA’s biologics center. It also does not provide pre-2016 changes in the same system.

A missing entry therefore has several possible explanations. The product may be outside scope; the change may concern another section; the event may predate 2016; the search term may not match; or there may simply be no covered change. None of those possibilities proves that the product is risk-free, unapproved, or unchanged in every respect.

The database is also not an adverse-event counter, recall list, shortage database, or approval database. Those questions require different FDA resources.

03

A step-by-step search workflow

Begin with both the brand name and active ingredient. A class search can identify leads, but a product-specific result is safer because the same ingredient may appear in different applications, indications, routes, or formulations. Search by date when monitoring recent changes across products, then narrow each result to the exact application.

Open the result and record the labeling section, approval date, and displayed additions or deletions. Avoid summarizing a deletion as a reversal until the surrounding replacement language is understood. Some updates reorganize text, clarify wording, or move information rather than simply adding or eliminating a risk.

Next, open the most recent full prescribing information in Drugs@FDA. Confirm that the current document date is at least as recent as the change record and read the relevant section in context. Save the direct URLs and access date in the research record.

• →Search brand and established names
• →Match the exact application and product
• →Record section and approval date
• →Compare deleted and added language
• →Open the latest complete FDA label
• →Check separate alerts, recalls, and approval history when relevant

04

How to interpret additions, removals, and stronger language

An added warning shows that new safety information was incorporated into labeling; it does not by itself measure how frequently an event occurs or prove causation in every reported case. Read the label for any incidence data, population limits, monitoring language, and the evidence context FDA provides.

A removed warning can reflect an updated evidence assessment, harmonization across products, or another regulatory reason. It does not mean the medicine has no risks. Report the exact removed topic and retain the rest of the current safety profile rather than publishing a blanket “FDA says it is safe” claim.

Stronger wording may change where or how prominently a risk appears. Boxed Warnings, Contraindications, and Warnings and Precautions have different functions. A comparison should identify the section instead of treating all label text as equivalent.

05

Using the database in provider and marketing research

When a provider says FDA removed, added, or confirmed a warning, search the record and compare the provider’s date and wording. Accurate marketing should identify the approved product and should not extend a label change to a compounded preparation, a different route, or an investigational substance.

A provider also should not use the absence of a search result as evidence that an unapproved peptide has a clean safety record. Unapproved products generally do not have FDA-approved prescribing information, while compounded drugs do not undergo FDA premarket approval. Sparse official labeling can mean less reviewed information, not lower risk.

For living articles, add an update trigger: recheck the SrLC database and current label before repeating a dynamic safety statement. This is especially important when the source article predates the latest label supplement.

06

Limits and clinical boundaries

The SrLC database is a research tool, not a diagnostic tool. It cannot determine whether a symptom is caused by a medicine, whether an individual should use a product, or how treatment should change. Those decisions require a licensed clinician with the current label and patient-specific information.

Urgent symptoms should be handled through appropriate medical or emergency channels. Suspected adverse events and product problems can be reported to FDA through MedWatch after immediate care needs are addressed.